6 results on '"van der Weijden, Mignon A. C."'
Search Results
2. Reply.
- Author
-
Rusman, Tamara, van der Weijden, Mignon A. C., Nurmohamed, Michael T., van der Bijl, Carmella M. A., van der Laken, Conny J., Bet, Pierre M., Landewé, Robert B. M., de Winter, Janneke J. H., Boden, Bouke J. H., and van der Horst‐Bruinsma, Irene E.
- Subjects
- *
DRUG efficacy , *INFLAMMATION , *BACKACHE , *ETANERCEPT - Published
- 2021
- Full Text
- View/download PDF
3. IL10 GGC haplotype is positively and HLA-DQA1*05-DQB1*02 is negatively associated with radiographic progression in undifferentiated arthritis.
- Author
-
Ursum J, van der Weijden MAC, van Schaardenburg D, Prins APA, Dijkmans BAC, Twisk JWR, Crusius JBA, van der Horst-Bruinsma IE, Ursum, Jennie, van der Weijden, Mignon A C, van Schaardenburg, Dirkjan, Prins, Arend P A, Dijkmans, Ben A C, Twisk, Jos W R, Crusius, Jakob B A, and van der Horst-Bruinsma, Irene E
- Published
- 2010
- Full Text
- View/download PDF
4. Is Treatment in Patients With Suspected Nonradiographic Axial Spondyloarthritis Effective? Six-Month Results of a Placebo-Controlled Trial.
- Author
-
Rusman T, van der Weijden MAC, Nurmohamed MT, Landewé RBM, de Winter JJH, Boden BJH, Bet PM, van der Bijl CMA, van der Laken C, and van der Horst-Bruinsma IE
- Subjects
- Adult, Bone Marrow diagnostic imaging, Comorbidity, Edema diagnostic imaging, Female, Humans, Inflammatory Bowel Diseases epidemiology, Magnetic Resonance Imaging, Male, Middle Aged, Psoriasis epidemiology, Sacroiliac Joint diagnostic imaging, Spondylarthropathies diagnostic imaging, Spondylarthropathies epidemiology, Treatment Outcome, Young Adult, Antirheumatic Agents therapeutic use, Etanercept therapeutic use, Spondylarthropathies drug therapy
- Abstract
Objective: To investigate the efficacy of 16-week treatment with etanercept (ETN) in patients with suspected nonradiographic axial spondyloarthritis (SpA)., Methods: Tumor necrosis factor inhibitor-naive patients with inflammatory back pain with at least 2 SpA features and high disease activity (Bath Ankylosing Spondylitis Disease Activity Index score ≥4), without the requirement of a positive finding on magnetic resonance imaging (MRI) of the sacroiliac (SI) joint and/or elevated C-reactive protein (CRP) level, were randomized (1:1) to receive ETN (n = 40) or placebo (n = 40) for 16 weeks and subsequently were followed up for a further 8 weeks (to 24 weeks from baseline) without study medication. The primary end point was the Assessment of SpondyloArthritis international Society 20 (ASAS20) response at 16 weeks. Secondary end points included the Ankylosing Spondylitis Disease Activity Score (ASDAS) and changes in disease parameters, including the Bath Ankylosing Spondylitis Metrology Index (BASMI), CRP level, erythrocyte sedimentation rate (ESR), and Spondyloarthritis Research Consortium of Canada index scores (MRI of the SI joint), after 16 and 24 weeks., Results: Patient characteristics at baseline were comparable between the ETN and placebo groups. At 16 weeks, there was no significant difference in the percentage of patients exhibiting ASAS20 response between the ETN group (6 patients [16.7%]) and the placebo group (4 patients [11.1%]) (relative risk 0.7 [95% confidence interval 0.2-2.2], P = 0.5). Only the ESR showed more improvement in the ETN group compared to the placebo group at 16 weeks (decreases of 2.2 mm/hour and 1.4 mm/hour, respectively), but the difference did not reach statistical significance. Between 16 and 24 weeks, without study medication, the BASMI, CRP level, and ESR had worsened to a greater extent in the ETN group compared to the placebo group, with the difference being significant for the CRP level., Conclusion: This study shows that in patients with suspected nonradiographic axial SpA with high disease activity but without the requirement of a positive finding on SI joint MRI and/or elevated CRP level, treatment with ETN is not effective., (© 2020 The Authors. Arthritis & Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.)
- Published
- 2021
- Full Text
- View/download PDF
5. C-reactive protein polymorphisms influence serum CRP-levels independent of disease activity in ankylosing spondylitis.
- Author
-
Claushuis TA, de Vries MK, van der Weijden MA, Visman IM, Nurmohamed MT, Twisk JW, Van der Horst-Bruinsma IE, and Crusius JB
- Subjects
- Adult, Biomarkers blood, Cross-Sectional Studies, Female, Gene Frequency, Genetic Predisposition to Disease, Haplotypes, Humans, Linear Models, Logistic Models, Male, Middle Aged, Netherlands, Phenotype, Risk Factors, Severity of Illness Index, Spondylitis, Ankylosing diagnosis, Spondylitis, Ankylosing immunology, C-Reactive Protein antagonists & inhibitors, C-Reactive Protein genetics, Polymorphism, Single Nucleotide, Spondylitis, Ankylosing blood, Spondylitis, Ankylosing genetics
- Abstract
Objectives: C-reactive protein (CRP) levels are frequently used to determine disease activity in patients with ankylosing spondylitis (AS), but these levels may not reflect disease activity. We therefore investigated the influence of common single-nucleotide polymorphisms (SNPs) in the CRP gene on CRP levels in AS patients. Additionally, the relation between CRP levels and BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) was examined., Methods: This exploratory cross-sectional study included 189 Dutch AS patients. CRP SNPs rs2794521, rs3091244, rs1800947 and rs876538 were genotyped and haplotypes constructed. Linear regression analysis was used for the association between SNPs and CRP levels, with correction for confounders non-steroidal anti-inflammatory drugs use, body mass index, smoking, age, gender and disease activity (BASDAI)., Results: Only 52% of AS patients with a high disease activity (BASDAI ≥4) showed a high CRP level (≥10mg/L), whereas the others did not. In AS patients, CRP levels changed with different genotypes, with genotype CA of tri-allelic (C>T>A) SNP rs3091244 showing higher CRP levels in comparison with genotype CC (CA: 18.6 mg/L vs. CC: 8.3 mg/L; p=0.02). Carriers of haplotype 5 (tagged by allele A of rs3091244) had a higher risk to express a CRP ≥10 mg/L (OR=2.9, 95%CI 1.0-8.3; p=0.05) when compared with non-carriers., Conclusions: In AS, patients with high disease activity often do not show corresponding high CRP levels. We found that CRP levels vary with different CRP genotype in AS patients. Carrying distinct genetic variants might play a role in certain AS patients who show low CRP levels despite high disease activity (as well as high CRP levels with low disease activity). This observation may be important for the interpretation of disease activity scores that incorporate CRP levels, like the ASDAS.
- Published
- 2015
6. Bone formation rather than inflammation reflects ankylosing spondylitis activity on PET-CT: a pilot study.
- Author
-
Bruijnen ST, van der Weijden MA, Klein JP, Hoekstra OS, Boellaard R, van Denderen JC, Dijkmans BA, Voskuyl AE, van der Horst-Bruinsma IE, and van der Laken CJ
- Subjects
- Adult, Carbon Radioisotopes, Female, Fluorodeoxyglucose F18, Humans, Inflammation diagnostic imaging, Male, Middle Aged, Pilot Projects, Spondylitis, Ankylosing pathology, Young Adult, Osteogenesis physiology, Positron-Emission Tomography methods, Spondylitis, Ankylosing diagnostic imaging, Tomography, X-Ray Computed methods
- Abstract
Introduction: Positron Emission Tomography - Computer Tomography (PET-CT) is an interesting imaging technique to visualize Ankylosing Spondylitis (AS) activity using specific PET tracers. Previous studies have shown that the PET tracers [18F]FDG and [11C](R)PK11195 can target inflammation (synovitis) in rheumatoid arthritis (RA) and may therefore be useful in AS. Another interesting tracer for AS is [18F]Fluoride, which targets bone formation. In a pilot setting, the potential of PET-CT in imaging AS activity was tested using different tracers, with Magnetic Resonance Imaging (MRI) and conventional radiographs as reference., Methods: In a stepwise approach different PET tracers were investigated. First, whole body [18F]FDG and [11C](R)PK11195 PET-CT scans were obtained of ten AS patients fulfilling the modified New York criteria. According to the BASDAI five of these patients had low and five had high disease activity. Secondly, an extra PET-CT scan using [18F]Fluoride was made of two additional AS patients with high disease activity. MRI scans of the total spine and sacroiliac joints were performed, and conventional radiographs of the total spine and sacroiliac joints were available for all patients. Scans and radiographs were visually scored by two observers blinded for clinical data., Results: No increased [18F]FDG and [11C](R)PK11195 uptake was noticed on PET-CT scans of the first 10 patients. In contrast, MRI demonstrated a total of five bone edema lesions in three out of 10 patients. In the two additional AS patients scanned with [18F]Fluoride PET-CT, [18F]Fluoride depicted 17 regions with increased uptake in both vertebral column and sacroiliac joints. In contrast, [18F]FDG depicted only three lesions, with an uptake of five times lower compared to [18F]Fluoride, and again no [11C](R)PK11195 positive lesions were found. In these two patients, MRI detected nine lesions and six out of nine matched with the anatomical position of [18F]Fluoride uptake. Conventional radiographs showed structural bony changes in 11 out of 17 [18F]Fluoride PET positive lesions., Conclusions: Our PET-CT data suggest that AS activity is reflected by bone activity (formation) rather than inflammation. The results also show the potential value of PET-CT for imaging AS activity using the bone tracer [18F]Fluoride. In contrast to active RA, inflammation tracers [18F]FDG and [11C](R)PK11195 appeared to be less useful for AS imaging.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.